Morgan Stanley said many investors are worried about newly public ride-hailing company Uber's path to profitability as well as "growth durability."
However, "we like this set-up…particularly as we're entering a 2H of easing Y/Y ride sharing growth compares, an relatively stable competitive landscape in the US and abroad, and a still-long runway," analysts said. Uber's ability to beat near-term ride sharing bookings is "key to turning investor sentiment and interest," they said.
The firm's analysts are betting that biotech company Gilead Science's HIV franchise will help drive a beat on second-quarter revenue. "We are also lower on 1H spending, which in combination with higher revenues would position GILD well for a 2Q19 EPS beat," the analysts said.American Express is the only company on the Morgan Stanley's list in the financial sector. The firm said it sees revenue growth recceleration for the company on the back of a "fading" U.S. dollar strength, strong retail sales growth, "wealth effect on Amex cardmember spending," and low interest rates.
. Analysts said the company will be forced to lower prices as "underlying demand appears to have decelerated."
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: WSJ - 🏆 98. / 63 Read more »